Active Biotech AB (STO:ACTI), a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer, announced on Thursday that initial data from the phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented by global coordinating principal investigator, Dr Ralf Railmann, at the scientific conference 'European Huntington's Disease Network (EHDN
) plenary meeting 2018' to be held from 14 September 2018 to 16 September 2018 in Vienna.
Aziz NA, Jurgens CK, Landwehrmeyer GB, EHDN
Registry Study Group, van Roon-Mom WM, van Ommen GJ, et al.
According to the chairman of the European Huntington's Disease Network (EHDN
), GB Landwehrmeyer, this meta-analysis indicates that Huntexil has the potential to be an important therapeutic advance in Huntington's disease patients.